LupusForum_Highlights_EULAR2022
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
EULAR 2022<br />
Congress Preview<br />
Lupus<br />
Chair’s Introduction<br />
Dear Colleagues,<br />
Welcome to the Lupus Forum EULAR 2022 Congress Preview. This pre-congress brochure provides you with all you need to know<br />
about the lupus content at EULAR this year, including the plenaries, posters, and Chair’s picks of the content that you shouldn’t miss.<br />
Poster Views on Wednesday include safety data for belimumab (POS0712), baricitinib (POS0714), and rituximab (POS1320),<br />
the hypersensitivity profile of anifrolumab (POS0708) and data on BICLA and BILAG organ domain responses in patients receiving<br />
anifrolumab (POS0709), among others.<br />
Thursday morning sees the What’s New In session focus on systemic lupus erythematosus, with Professor Thomas Dörner<br />
presenting “From pathogenesis to new therapies”.<br />
A Clinical Science Plenary on Friday spotlights joint and skin involvement in SLE, with the Lupus Forum’s Dr Victoria Werth and<br />
myself presenting, alongside Professor Annamaria Iagnocco. Also on Friday, there are oral abstract presentations in the Recent<br />
Novelties in SLE/Sjogren and APS session on voclosporin efficacy in achieving proteinuria treatment targets in lupus nephritis<br />
(OP0285), and the pharmocodynamic effect of sequential belimumab and rituximab (OP0281).<br />
It’s worth taking the opportunity to explore the Posters on Friday, with interesting submissions on voclosporin for lupus nephritis<br />
(POS0186), Phase 3 data on efficacy and safety of baricitinib in SLE (POS0190), the effect of belimumab on SRI-4 response<br />
(POS0183), and atacicept impact on renal function (POS0189), both in SLE.<br />
Saturday sees a dedicated poster tour, Systemic Lupus Erythematosus: Monitoring and Management, with many posters of interest.<br />
I’d like to draw your attention to two in particular, focusing on SLE and the improvement of mucocutaneous manifestations in<br />
patients treated with anifrolumab (POS0367), and early improvement in physician global assessment as a predictor of long-term<br />
retention of belimumab treatment (POS0368).<br />
We add new content to the Lupus Forum regularly, with monthly slide summaries of key publications, podcasts discussing recent<br />
advances, and congress materials like these. You can register for updates at lupus-forum.com or keep up to date by following us on<br />
Twitter @<strong>LupusForum</strong> and on LinkedIn by searching “Lupus Forum”.<br />
However you choose to attend EULAR 2022, whether in person or virtually, I hope you find our selection of highlights useful and that<br />
you enjoy the meeting.<br />
Kind regards,<br />
Ed Vital<br />
Associate Professor, University of Leeds<br />
Key Lupus Content<br />
Wednesday, 01 June 2022<br />
Chairman’s Picks<br />
All day Poster View 4<br />
POS0705<br />
Dilemma of Belimumab Therapy (Dis)Continuation During Pregnancy: Results of a Retrospective Study in EudraVigilance<br />
Nafise Ghalandari<br />
POS0707<br />
POS0708<br />
POS0709<br />
POS0712<br />
POS0714<br />
POS0719<br />
Potential Use of Belimumab in Lupus Patients from Argentine Cohort According Disease Activity State<br />
Rosana Quintana<br />
Evaluating the Hypersensitivity Profile of Anifrolumab and the Need for Preinfusion Prophylactic Treatment in Patients with SLE<br />
Kenneth C Kalunian<br />
Sustained BICLA and BILAG Organ Domain Responses in Patients with Systemic Lupus Erythematosus (SLE) Receiving<br />
Anifrolumab in Two Phase 3 Trials<br />
Ronald van Vollenhoven<br />
Year-4 Observational Follow-Up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a<br />
Phase 4, 52-Week, Randomised, Double-Blind Placebo-Controlled Safety Study<br />
Saira Sheikh<br />
Pooled Safety Analysis of Baricitinib in Patients with Systemic Lupus Erythematosus: Results from Three Randomised,<br />
Double-Blind, Placebo-Controlled, Clinical Trials<br />
Thomas Dörner<br />
Rapid Efficacy of Anifrolumab in Multiple Subtypes of Recalcitrant Cutaneous Lupus Parallels Discrete Changes in<br />
Transcriptomic and Cellular Biomarkers<br />
Lucy Marie Carter<br />
All day Poster View 10<br />
POS1320<br />
Safety And Efficacy of Rituximab in Patients with Juvenile Systemic Lupus Erythematosus: The Preliminary Data of<br />
Retrospective Cohort Study<br />
Rinat Raupov
Chairman’s Picks<br />
Thursday, 02 June 2022<br />
10:30–<br />
11:07<br />
What’s New In<br />
Systemic Lupus Erythematosus<br />
From Pathogenesis to New Therapies: What is New in SLE?<br />
Thomas Dörner<br />
Friday, 03 June 2022<br />
13:30–<br />
14:45<br />
10:30 –<br />
12:00<br />
OP0281<br />
OP0285<br />
12:00–<br />
13:30<br />
POS0183<br />
POS0186<br />
POS0189<br />
POS0190<br />
Clinical Science Session<br />
Joint and Skin Involvement in SLE<br />
Therapeutic Algorithms to Treat Cutaneous Lupus: What is New?<br />
Victoria Werth<br />
The Role of Imaging in the Assessment of Joint Involvement in SLE<br />
Annamaria Iagnocco<br />
Joint Involvement in SLE: Clinical Assessment, Role of Biomarkers and New Therapeutic Options<br />
Edward Vital<br />
Oral Abstract Presentation Session<br />
Recent Novelties in SLE/Sjogren and APS<br />
Pharmacodynamic Effect of Sequential Belimumab (BEL) and Rituximab (RTX) Therapy in Patients (Pts) with Systemic<br />
Lupus Erythematosus (SLE): The Phase 3, Randomised, Placebo-Controlled BLISS-BELIEVE Study<br />
Y.K. Onno Teng<br />
Voclosporin is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations<br />
Hans-Joachim Anders<br />
Poster View Auditorium 7<br />
New Options in SLE-Sjogren and APS<br />
The Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with Systemic Lupus Erythematosus:<br />
Results of a Large Integrated Analysis<br />
George Bertsias<br />
Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study<br />
Amit Saxena<br />
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)<br />
David Isenberg<br />
Efficacy and Safety of Baricitinib in Patients with Systemic Lupus Erythematosus: Results from Two Randomised,<br />
Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Studies<br />
Eric F. Morand<br />
Saturday, 04 June 2022<br />
10:15–<br />
11:45<br />
POS0367<br />
POS0368<br />
Poster View Auditorium 10<br />
Systemic Lupus Erythematosus: Monitoring and Management<br />
Improvement of Individual Mucocutaneous Manifestations in Patients with Systemic Lupus Erythematosus Treated<br />
with Anifrolumab<br />
Victoria Werth<br />
Early (3 Months) Improvement in Physician Global Assessment of Disease Activity Predicts Long-Term Retention of<br />
Belimumab Treatment in SLE: A Multicentre Observational Study of 184 Patients<br />
George Bertsias<br />
Developed<br />
under the<br />
auspices of:<br />
Supported with<br />
an educational<br />
grant from:
Change language